




ASO VISUAL ABSTRACT


ASO Visual Abstract: Effectiveness of a Short Duration of Neoadjuvant Endocrine Therapy in Patients with HR+ Breast Cancer—An NCDB Analysis (2004–2016)

Macy M. Goldbach, BS¹ , Laura Burkbauer, BA¹, Tina Bharani, MD¹, Austin D. Williams, MD, MEd³, Luke Keele, PhD², Jami Rothman, MD^{1,4}, Rachel Jankowitz, MD⁴, and Julia C. Tchou, MD, PhD, FACS^{1,4}

¹Division of Endocrine and Oncologic Surgery, Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; ²Division of Epidemiology and Biostatistics, Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; ³Department of Surgery, Lankenau Medical Center, Wynnewood, PA; ⁴Rena Rowan Breast Center, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

Using data from the NCDB, we found that short NET duration did not result in an inferior objective response rate (<https://doi.org/10.1245/s10434-021-10287-5>). Our results support the use of a short NET duration to bridge surgery delay during the COVID-19 pandemic.

DISCLOSURE Authors have no financial relationships or conflicts of interest relevant to this article to disclose.



Macy M. Goldbach and Laura Burkbauer have contributed equally to this work.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© Society of Surgical Oncology 2021

Published Online: 28 June 2021

J. C. Tchou, MD, PhD, FACS

e-mail: Julia.Tchou@pennmedicine.upenn.edu